AntibodyTargeted-Drug Conjugates 2015

13-15 April 2015, Crowne Plaza Porto, Porto, Portugal

  • Increase font size
  • Default font size
  • Decrease font size

Introduction

The Targeted Drug-Conjugates Delivery Conference – New Developments & Updates

The concept of using  biologics and particles including monoclonal antibodies to deliver drugs to disease targets such as cancer cells has been explored for decades, with early work surrounding nonspecific targets and drugs with low potencies. These studies highlighted the importance of critical parameters, such as antigen and tumor target selection, linker stability, drug potency, pharmacokinetics, and conjugation methodology, in developing effective targeted drug conjugates with acceptable safety/ toxicity profiles.

The inaugural ATDC 2015 New Developments & Updates conference to be held in Porto, Portugal in April 2015 will aim to examine the concept and future of targeted drug delivery systems to include antibodies/bispecific antibodies/proteins/nanoparticles and other biologics.

The ATDC 2015 scientific programme will include keynote lectures, contributed papers and poster presentations emphasising all key aspects and recent developments surrounding targeted drug delivery systems.

Abstracts for oral and poster presentation are called for – please see the participation section for abstract submission details.

Scientific Advisory Panel

John A. Flygare (Genentech Inc, South San Francisco, California, USA)
Greg Bleck (Catalent Pharma Solutions, Somerset, New Jersey, USA)
Victor Goldmacher (ImmunoGen Inc., Waltham, Massachusetts, USA)
John Lambert (ImmunoGen Inc., Waltham, Massachusetts, USA)
Roger R. Beerli (NBE-Therapeutics LLC, Basel, Switzerland)
Christoph Rader (Scripps Research Institute, Jupiter, Florida, USA)
Michael Firer (Ariel University, Ariel, Israel)
Christoph Mamot (Kantonsspital Aarau AG, Aarau, Switzerland)
Alain Beck (Centre d’Immunologie Pierre Fabre, St Julien-en-Genevois, France)
Hanspeter Gerber (Pfizer Worldwide R&D, Pearl River, USA)
Philip Howard (Spirogen Ltd, London, UK)
Aaron K. Sato (SUTRO Biopharma, South San Francisco, California, USA)

Conference Scope and Topics

  • Novel ADC targets/ADC target discovery/target disease indications (including  non-cancer targets)
  • Novel payloads/modes of action (beyond tubulin binders)
  • Biological components (antibody & antibody-like formats; molecularly defined conjugation sites)
  • Chemical components: Linker/payload combinations; optimization of linker chemistry; cleavable linkers
  • Next generation ADCs (site-specifically conjugated, including enzymatic conjugation
  • Immunotoxins
  • Chemistry approaches: mediating high toxicity of new warheads currently in use
  • Chemical modifications of ADC structure and linkers
  • Improving the therapeutic index – toxicity reduction efforts avoiding efficacy reduction
  • Other carrier/delivery possibilities beyond antibodies and bispecific antibodies (nanoparticles, peptides, aptamers, hormones and their analogues, small molecules, liposomes, vitamins)
  • Manufacturing/Regulatory issues
  • Process development (robustness, scalability)
  • Clinical stage ADCs/ongoing clinical trials, clinical translation
 

ATDC 2015 Delegates

Login details will be supplied after you have registered for the event.


ATDC 2015 Sponsors

  • Oncozine
  • NBE Therapeutics
  • ONdrugDelivery
  • Pfizer Oncology
  • Sutro Biopharma
  • LinXis
  • NatureGeneTherapy.com
  • Aldevron
  • Biovest
  • Genentech
  • ImmunoGen
  • Synthon
  • DNAvaccine.com
  • ADC Review
  • Catalent
  • Nascent Biologics

ATDC 2015 Downloads

ATDC 2015 Leaflet

ATDC 2015 Mailing List

Name
E-mail Address
What is 3+2-1?